// App-Quantinova.ai

OP0229 : GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)

Researchers

Presenter

  • S. Siebert

Principal Investigators

  • I. Mcinnes

  • M. J. Loza

  • K. MA

  • K. Leander

  • V. Lakshminarayanan

  • C. Franks

  • P. Cooper

  • K. Sweet

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Janssen Research & Development, Raritan, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • C reactive protein

  • C-C Motif Chemokine Ligand 22

  • C-C Motif Chemokine Ligand 4

  • Chitinase 3 Like 1

  • C-X-C motif chemokine ligand 8

  • Intercellular adhesion molecule 1

  • Interferon-gamma

  • Interleukin 1 beta

  • Interleukin 10

  • Interleukin 13

  • Interleukin 17A

  • Interleukin 17B

  • Interleukin 4

  • Interleukin 6

  • Interleukin-2

  • Interleukin-22

  • Serum amyloid A

  • Vascular cell adhesion molecule 1

Drug/Treatment

  • guselkumab (IV)

  • ICAM-1

  • Interferon Gamma

  • IFN-lambda

  • Interleukin-10

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • BMS Infotech

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved